William Blair Has Negative Estimate for DVAX Q1 Earnings

Dynavax Technologies Co. (NASDAQ:DVAX - Free Report) - William Blair cut their Q1 2025 earnings per share (EPS) estimates for Dynavax Technologies in a research note issued to investors on Friday, February 21st. William Blair analyst M. Phipps now forecasts that the biopharmaceutical company will post earnings of $0.03 per share for the quarter, down from their previous estimate of $0.04. William Blair has a "Outperform" rating on the stock. The consensus estimate for Dynavax Technologies' current full-year earnings is $0.32 per share. William Blair also issued estimates for Dynavax Technologies' Q2 2025 earnings at $0.09 EPS, Q3 2025 earnings at $0.12 EPS, Q4 2025 earnings at $0.04 EPS, FY2025 earnings at $0.28 EPS, Q1 2026 earnings at $0.11 EPS, Q2 2026 earnings at $0.18 EPS, Q3 2026 earnings at $0.21 EPS, Q4 2026 earnings at $0.11 EPS and FY2026 earnings at $0.61 EPS.

Other analysts have also issued reports about the company. The Goldman Sachs Group lowered Dynavax Technologies from a "neutral" rating to a "sell" rating and decreased their target price for the company from $15.00 to $12.00 in a research report on Tuesday, February 11th. StockNews.com raised Dynavax Technologies from a "hold" rating to a "buy" rating in a research report on Monday. Finally, HC Wainwright reiterated a "buy" rating and issued a $31.00 target price on shares of Dynavax Technologies in a report on Friday, February 21st.

Dynavax Technologies Stock Up 1.8 %

Shares of NASDAQ DVAX traded up $0.24 during trading on Monday, hitting $13.65. 53,547 shares of the company traded hands, compared to its average volume of 1,793,615. The firm has a market capitalization of $1.79 billion, a price-to-earnings ratio of 75.36 and a beta of 1.32. The business's fifty day moving average is $12.83 and its 200 day moving average is $12.06. The company has a debt-to-equity ratio of 0.33, a quick ratio of 12.34 and a current ratio of 13.23. Dynavax Technologies has a fifty-two week low of $9.74 and a fifty-two week high of $14.05.

Dynavax Technologies (NASDAQ:DVAX - Get Free Report) last released its earnings results on Thursday, February 20th. The biopharmaceutical company reported $0.05 earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of $0.05. The company had revenue of $72.03 million for the quarter, compared to the consensus estimate of $72.70 million. Dynavax Technologies had a net margin of 9.85% and a return on equity of 4.22%.

Institutional Trading of Dynavax Technologies

Institutional investors and hedge funds have recently modified their holdings of the stock. Deep Track Capital LP grew its holdings in Dynavax Technologies by 42.0% during the fourth quarter. Deep Track Capital LP now owns 17,791,486 shares of the biopharmaceutical company's stock worth $227,197,000 after buying an additional 5,265,000 shares in the last quarter. Deerfield Management Company L.P. Series C boosted its holdings in Dynavax Technologies by 23,990.1% during the 4th quarter. Deerfield Management Company L.P. Series C now owns 5,193,823 shares of the biopharmaceutical company's stock worth $66,325,000 after acquiring an additional 5,172,263 shares during the last quarter. Assenagon Asset Management S.A. purchased a new position in Dynavax Technologies during the 3rd quarter worth $8,291,000. Norges Bank bought a new stake in shares of Dynavax Technologies in the 4th quarter worth $7,762,000. Finally, D. E. Shaw & Co. Inc. raised its holdings in shares of Dynavax Technologies by 34.0% in the fourth quarter. D. E. Shaw & Co. Inc. now owns 1,918,340 shares of the biopharmaceutical company's stock valued at $24,497,000 after purchasing an additional 486,981 shares during the last quarter. 96.96% of the stock is owned by hedge funds and other institutional investors.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.